Clinical Trial Operations

Biotech and pharma companies don’t struggle because of weak science.
They struggle because execution breaks down between strategy and the site level.

Timelines slip.
Enrollment underperforms.
Sites disengage.
And what should be a clear path to patients becomes fragmented.

This is where I work.

I partner with biotech and pharmaceutical organizations to stabilize, align, and accelerate clinical trial execution using a proven operational framework:

Before accelerating, we assess what’s actually happening—not what’s in the plan.

Focus Areas:

• Study startup bottlenecks (contracts, budgets, feasibility delays) 
• Site selection and activation gaps 
• CRO and vendor misalignment 
• Protocol operational complexity 
• Enrollment assumptions vs. site reality 

Outcome:
Clear visibility into risks, inefficiencies, and execution barriers fast.

Most failures happen in the disconnect between sponsor expectations and site capabilities.

Focus Areas:

• Sponsor ⇄ CRO ⇄ Site alignment 
• Feasibility redesign based on real-world site performance 
• Site engagement and communication models 
• Enrollment strategy grounded in operational reality 
• KPI restructuring for accountability and speed 

Outcome:
A unified execution model where all stakeholders operate with clarity and shared priorities.

With alignment in place, execution becomes predictable, measurable, and scalable.

Focus Areas:

• Enrollment acceleration strategies 
• Site performance optimization 
• Study rescue and recovery plans 
• Operational playbooks for repeatable success 
• Leadership support for execution discipline 

Outcome:
Faster timelines. Stronger site relationships. Reliable delivery.

I work across critical inflection points in clinical development:

• Early Phase (Phase I–II): Operational readiness and site strategy 
• Mid/Late Phase (Phase II–III): Enrollment acceleration and execution optimization 
• Study Rescue: Underperforming trials requiring immediate intervention 
• Site Network Strategy: Building high-performing, sponsor-aligned site ecosystems

Traditional model:
Biotech → CRO → Site
Fragmented. Reactive. Delayed.

Reset · Realign · Restart model:
Biotech ⇄ Site (Aligned)
CRO = Execution support layer

This shift creates:

• Faster decision-making 
• Stronger site ownership 
• Higher enrollment performance 
• Better trial predictability